Initial orders point to start of commercialisation

Rex Bionics 6 January 2016 Update

Rex Bionics

Initial orders point to start of commercialisation

H116 results

Tech hardware & equipment

6 January 2016

Price

43.5p

Market cap

£8m

Net cash (£m) at September 2015

3.7

Shares in issue

17.8m

Free float

63%

Code

RXB

Primary exchange

AIM

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(6.5)

(13.0)

(40.0)

Rel (local)

(5.1)

(11.3)

(38.7)

52-week high/low

72.5p

43.5p

Business description

Rex Bionics develops and produces exoskeletons to help assist in the rehabilitation and improve the mobility of patients with spinal cord injury (SCI) and other lower limb mobility problems.

Next events

FY16 results

June 2016

Analysts

Marla Backer

+1 646 653 7030

Moira Daw

+61 (0)29 258 1160

Rex Bionics is a research client of Edison Investment Research Limited

Rex Bionics, a pioneer in the medical exoskeleton field, has recently reported a number of encouraging updates, including interim financial results, new distributors for the key US and China markets and positive interim metrics from its RAPPER II clinical trial. The company is focused on rehabilitating and improving mobility in patients with spinal cord injury. Its two key markets are rehabilitation centres and home use. Clinical trials demonstrating the medical benefits to patients and commercial benefits to rehabilitation centres have produced promising results data to date.

Year
end

Revenue (£m)

PBT*
(£m)

EPS*
(p)

DPS
(p)

P/E
(x)

Yield
(%)

11/13

0.0

(0.5)

(1.4)

0.0

N/A

N/A

03/15

0.2

(4.8)

(46.9)

0.0

N/A

N/A

03/16e

0.9

(5.3)

(33.2)

0.0

N/A

N/A

03/17e

5.0

(5.5)

(30.7)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Initial sales are encouraging

Rex released its interim results on 8 December 2015, with several trends that appear to be positive. It sold three units in H116, which represent the first revenues from product sales since Rex’s 2014 IPO and is thus an encouraging sign of the commercial potential of the device. With additional customer orders already in place, the company expects H216 sales to be higher than H1. However, we are trimming our FY16 sales forecast to £910k from £1m and lowering our operating expense forecast, largely reflecting cost containment efforts and the benefits of recent FX trends.

Progress in US market

Rex has been demonstrating the Rex exoskeleton in the US, where it has received positive feedback. We view this as the start of a phased-in commercialisation strategy for the US market, where the company expects to place several additional units in 2016 after recently establishing a sales distribution relationship. Separately, the New Zealand government has agreed to provide up to NZ$100,000 in funding to support Rex's initiatives in the US, which we view as another positive factor supporting the company’s commercialisation efforts.

Valuation: Clinical trials, product sales key

Following a 40% drop in the share price year to date, Rex is trading at a significant discount to its peers on a price to sales basis, at only 1.5x FY17e sales versus an average of 11.9x (Ekso Bionics and ReWalk Robotics for CY16e). Moreover, based on our current estimates, a reverse DCF with 15% WACC and 3% terminal growth implies that annual sales need to reach only c 130 units by 2020 to justify the share price. If the company’s sales follow an upward trend, clinical trials continue to show positive metrics and FDA clearance is obtained for the US personal market, we would expect these to be catalysts to help close the gap between Rex’s shares and those of its closest peers.

Business update

Interim financial results: Initial sales are encouraging

The company released its interim results on 8 December 2015, with several positive metrics. The company sold three Rex units during H116, with two sales in the US and one in Hong Kong. Importantly, these sales represent the first revenues the company has recorded from sales of exoskeleton units since its 2014 IPO and are thus an encouraging sign of the commercial potential the device has, in our view. Of the two sales in the US, one was made to TIRR Memorial Hermann in Houston. With additional customer orders already in place, the company expects H216 sales to be higher than H1.

Reflecting the sale of the first three Rex units, the company generated product revenues of £0.18m during H1. By way of comparison, Rex generated no product sales revenue in the same period of FY15. The three units included two that were sold to distributors essentially at cost, with the third to a hospital at the list price. The company provided a fourth as a replacement for an older unit that a US hospital had been using for patient rehabilitation. This likely affected the total cost of sales. The upgrade is consistent with the company’s US commercialisation strategy, as we believe the new unit can better show the efficacy of the Rex device. The company recorded a negative gross profit of £0.1m for the period reflecting the manufacturing costs associated with the units that Rex sold and upgraded in the period.

Rex reported total administrative expenses of £2.5m, including amortisation of £0.38m on acquired IP related to the company's acquisition of its New Zealand subsidiary. The company recorded a net loss of £2.2m in H116 versus £2.3m in H115 (six months to 30 September 2014).

Exhibit 1: Summary H116 financial results (£000s)

H116

H115

Difference (%)

Sales (number of units)

3

0

N/M

Revenue

184

0

N/M

Cost of sales

(262)

(5)

N/M

Gross (loss)/profit

(78)

(5)

N/M

Loss from operations

(2,439)

(2,370)

2.9

Pre-tax loss

(2,285)

(2,370)

(3.6)

Income tax/(expense)

101

84

20.2

Net loss for the period

(2,184)

(2,286)

(4.5)

Loss per share from continuing operations (p)

(13.6)

(38.2)

(64.4)

Source: Rex Bionics, Edison Investment Research

The company’s cash reserves at 30 September 2015 were £3.7m compared to £4.4m at 31 March 2015. Net cash used to fund operating activities was £1.9m in H116, down from £2.5m in the same period of FY15. This was offset by net proceeds of £1.9m from the equity fund-raising Rex conducted in June 2015, which it expects will qualify for Enterprise Investment Scheme (EIS) tax relief, although it must still obtain formal confirmation from HMRC.

The company’s cash balance declined by £0.7m in H116, driven by investment spending of £0.1m and a negative foreign exchange impact of £0.6m related to the translation of New Zealand dollar-denominated net assets into sterling (GBP). During the period, the NZ dollar depreciated by approximately 20% relative to GBP. A significant proportion of Rex’s expenditures, particularly R&D and manufacturing costs, are NZ$-denominated. Management expects that if the NZ$ remains relatively weak compared to GBP and US$, it could have a further positive impact on the company’s operational results, as revenue is generally denominated in US dollars and GBP.


Changes to forecasts

We are trimming our sales forecast for FY16 to £910k from £1m, as sales to distributors could reduce the average selling price per unit in the near term. However, this change in revenue is nearly offset by our revised lower operating expense forecast, largely reflecting the company’s cost containment efforts (as shown in the H116 results) and the benefits of recent FX trends. As a result, our FY16 EBITDA forecast remains largely unchanged. The company has indicated that it will probably need to raise additional funds within the next 12 months – we have reflected this in the assumption of debt of £10m from the beginning of FY17 (compared to the assumption of £10m debt from FY16 as per our previous model). This reduces our interest expense forecast for FY16, resulting in a change in PBT and net income from -£5.7m to -£5.3m. We have also reflected the June equity raise, resulting in normalised EPS moving from -40.1p to -33.2p in FY16e and from -38.4p to -30.7p in FY17e.

Moving towards commercialisation

Progress in the US market

Rex has been demonstrating the Rex exoskeleton at the DMC Rehabilitation Institute of Michigan, where it has received positive feedback and has generated media coverage. In our view, this is the start of a phased-in commercialisation strategy for the US market, where the company expects to place several units in 2016. As noted, the company sold Rex units in the US during H116 and established a sales distribution relationship, which management believes will be key to developing the US market for the Rex exoskeleton.

Separately, the New Zealand government's international business development agency, New Zealand Trade and Enterprise, has agreed to provide up to NZ$100,000 in funding to support Rex's ongoing development of its business initiatives in the US, which we view as another positive factor supporting the company’s commercialisation efforts.

New distributors

Another positive move, we believe, is the recent relationships Rex has formed with distributors in important markets. In fact, one of the company’s primary goals in H116 has been to secure relationships with key distributors and commercial partners to facilitate its international commercialisation strategy. During H1, Rex appointed specialised distributors and strategic partners in the US, China, Hong Kong, Scandinavia, the Benelux countries and Russia.

US market: in the US, the company formed a distribution agreement with Ri, LLC, a specialist supplier of movement therapy equipment to neuro-rehabilitation clinics throughout the country. Ri, which intends to rebrand as Enable Me, is a privately owned distributor that is headquartered in St Petersburg, Florida. It was established more than a decade ago in 2003 by a seasoned rehabilitation industry specialist, Mike Laky, with whom Rex is working closely, according to management. Through its existing product range, it already has long-term contracts in place with leading US hospitals and covers a broad geographic footprint for Rex products. Rex is encouraged by the activities of its US distributor to date, which in less than three short months since the relationship was formalised has already booked demonstrations of the Rex exoskeleton through mid-2016.

China: in July 2015, the company appointed MAAB Group as its commercial partner in China. Headquartered in Hong Kong, MAAB Group is an investment and trading company that focuses on sourcing and bringing innovative medical technologies into China. Similar to Ri in the US, MAAB Group was also founded by industry veterans. Its expertise ranges from providing market access to assisting with sales and marketing.

MAAB will manage the company’s application process for regulatory approval from the China Food and Drug Administration (CFDA). It will also manage the sales, marketing and distribution of the Rex exoskeleton once it is approved. MAAB is already familiar with the product, as it had already begun limited pre-marketing. Management is optimistic that MAAB can launch a full product introduction as early as H216, pending formal approval from CFDA.

China's emerging middle class is growing rapidly, while the Chinese government has also increased its commitment to improving access to healthcare. Given the size of the market, management believes China could represent a sizeable market opportunity for Rex over time.

Other markets: the company also continues to engage in discussions with additional potential distributors in several other countries to advance its international commercialisation strategy. Management expects to announce further appointments in H2.

Positive interim clinical trial results

Rex completed its first clinical trial, RAPPER I (Robot-Assisted Physiotherapy Exercises with Rex) in Q115, which was an 11-patient study to assess the feasibility of carrying out sophisticated physiotherapy with the Rex. There were no adverse events (injuries or undue stress) and 10 of the patients were able to complete the exercises and use the Rex joystick effectively. The 11th patient could not participate in the trial because that person did not meet the size requirements.

A second trial (RAPPER II) involving 100 patients is underway. RAPPER II focuses on the safety and feasibility of the Rex as an assistive rehabilitation device from both the patient’s and the rehab centre’s points of view. On 1 June 2015 the company announced the enrolment of the first recruit into RAPPER II.

Management has noted that recruitment rates have been strong at the first trial centre, located in PhysioFunction in Northampton, UK. Moreover, management expects recruitment to accelerate in the near term, as it adds five new trial centres at major neuro-rehabilitation units in the UK, Australia and New Zealand.

Recruitment is also likely to be supported by positive results from an interim analysis of data from the first 20 patients involved in the trial. The interim results were recently presented at international neuro-rehabilitation conferences in Perth, Australia and Vienna. The key findings from this first interim analysis are shown in Exhibit 2 below.

Exhibit 2: RAPPER II interim results

Criteria

Description

Treatment success

19 out of 20 volunteers (95%) completed the walk/exercise protocol

Mean time

The mean time from transfer to mobilisation was seven minutes

Safe for patient use

There were no serious adverse events and no treatment-related adverse events.

Benefits of using Rex

100% of volunteers responded that they could "see the benefits of using REX regularly"

Weekly use of Rex

95% of volunteers responded that they would like to use the Rex on a weekly basis

Criteria

Treatment success

Mean time

Safe for patient use

Benefits of using Rex

Weekly use of Rex

Description

19 out of 20 volunteers (95%) completed the walk/exercise protocol

The mean time from transfer to mobilisation was seven minutes

There were no serious adverse events and no treatment-related adverse events.

100% of volunteers responded that they could "see the benefits of using REX regularly"

95% of volunteers responded that they would like to use the Rex on a weekly basis

Source: Rex Bionics

RAPPER II clinical trial interim data were also presented at the Australia and New Zealand Spinal Cord Society meeting last month. With these interim results showing that the Rex unit is safe for patient use, they are expected to facilitate the company’s commercialisation strategy for the Rex exoskeleton.

The first phase of the trial consisted of a single visit to the Rex clinic, a walk test and a set of exercises, with immediate follow-up. Interim analysis of the data based on the first cohort of 20 volunteers shows that the Rex unit can be used safely by people with spinal cord injury. 19 out of 20 volunteers (95%) were able to complete the walk exercise, with no serious adverse events and no treatment-related adverse events. Importantly, 95% of volunteers indicated that they would like to use the Rex unit on a weekly basis and 100% said they could "see the benefits of using Rex regularly”. Overall, management believes the Rex unit tests well against exoskeletons that do not provide hands-free aid, with volunteers indicating no upper body fatigue or pain. The next cohort will be designed to verify therapeutic value, including contribution to reduced pain and improved sleep patterns. Therapeutic designation would facilitate Rex’s ability to qualify for insurance reimbursements and commercialisation.

The next cohort of 20 patients will also include new and more detailed questionnaires, as well as an extended follow-up after seven days. Management expects to present results from the next cohort in around mid-2016.

Down the road, the company also intends to conduct trials for other indications such as stroke and MS, which would occur separately from the RAPPER I and RAPPER II trials because of the different levels of mobility and rehabilitation requirements those studies would require. Clinical trials will also be important in persuading insurance companies to reimburse users for both personal injury claims and health insurance purposes. One of Rex’s peers has announced that its device is covered by a major German insurance company, which is good news for the whole industry because it shows that at least some insurers are willing to reimburse users for exoskeleton devices.

Personal injury claims

Funding is crucial to adoption in the personal use market. There are a number of funding methods that could be used to purchase Rex devices: healthcare providers, charities, health insurance companies, personal injury claims and private payment from individuals. We view charities and healthcare providers as the main source of revenue initially, followed by personal unit sales paid for either by charities or through personal injury claims. Estimates on jeffries-solicitors.com suggest that up to 1,200 spinal cord injuries occur every year in the UK with most of these caused by road traffic accidents. According to claims.co.uk there are 50,000 people in the nation who must live with paralysis. The National Spinal Cord Injury Statistical Center at the University of Alabama estimates that there are roughly 12,000 new spinal cord injury cases in the US each year.

For funding to be provided through personal injury claims it is important that the courts set a precedent for awarding these devices for home use. Claims awards are likely to be driven by positive user statements, case studies and positive outcomes from clinical trials. Rehab facilities and providers of healthcare funding may also be incentivised to use the Rex unit because of the cost savings from requiring fewer physiotherapists per patient and the reduced cost of medical complications as a result of the patients sitting or lying down for long periods.

In terms of personal injury claims, the company is optimistic as a result of two recent judgements. The two main categories of customer for Rex Bionics are healthcare providers and individuals that request mobility devices such as Rex’s through personal injury claims and charities. This implies that the potential for funding a Rex device through awards under personal injury claims will be an increasing focus for management. The potential of this channel is illustrated by a recent award. Specifically, in September 2015, Ben Barnes became the first recipient of a British High Court damages settlement, enabling him to purchase his own Rex for use at home. Ben Barnes had sustained a spinal cord injury in a road traffic accident. He was awarded £550,000 for orthotics as part of his overall settlement, which included the cost of a Rex unit for home rehabilitation, as well as replacement Rex devices and associated maintenance costs. 

Separately, another UK man who sustained spinal cord damage as a result of alleged clinical negligence was recently awarded interim funding for an intensive course of robot-assisted physiotherapy with Rex, pending a final settlement of his insurance claim. The company has indicated that it expects to realise its first sale of the Rex P unit for personal use in FY16.

Promotional activities

The exoskeleton market is an emerging one and therefore still relatively unknown in the broader medical and patient communities. We view it positively that the company and other exoskeleton producers are engaged in promotional activities to support greater awareness of the devices, their benefits to patients and, in turn, to launch and grow this young market. Rex Bionics continues to conduct marketing and promotional efforts to drive greater awareness of Rex in international markets.

In H1, the company exhibited at several major international neuro-rehabilitation conferences, including in Boston, Dallas, Dubai, Rome and Shanghai. Rex was also featured on local and national television. Given how little known this emerging technology and market is, we view it positively that the press has begun to take notice.

Laying the groundwork for future technology upgrades

The company’s R&D in H1 was focused on design improvements, laying the groundwork to launch the next generation of Rex exoskeletons.

While using the exoskeleton with mind control technology probably does not have near-term commercial implications, the company’s device is being used in mind control research that could point to future trends. The Rex that the company sold to Houston’s TIRR Memorial Hermann marks the hospital’s second Rex unit, which we view as another positive sign. TIRR Memorial is conducting research on the feasibility of controlling the device with non-invasive Mind Control technology compared to the waist high control stick through which users currently control the Rex exoskeleton.

In addition, at the Rome 2015 meeting of Robotics: Science and Systems, there was a successful demonstration of the direction of the Rex exoskeleton using Mind Control technology. A young quadriplegic man from the UK with a C3 level complete spinal injury walked in the Rex device using Mind Control technology that was developed in collaboration with the Laboratory for Non-invasive Brain-Machine Interface Systems at the University of Houston in Texas and TIRR Memorial Hermann hospital.

Rex is also working with the Centre for Neuroprosthetics in Lausanne, Switzerland on research to advance the use of mind control of robots. To further this technology, Rex has developed an upgraded version of its software that allows researchers and therapists to record all the movements of a Rex in real time. Management believes this will be a valuable tool in the study of the biomechanics of the Rex system.

Key objectives for 2015/16

Rex continues to make progress on the five commercialisation priorities that management detailed in December 2014: 1) clinical data; 2) distributor recruitment; 3) reference centres; 4) US development; and 5) new medical applications. As noted, recently published analysis of interim data from the company’s RAPPER II clinical trial illustrates that the company’s device is safe for use by patients with more severe spinal cord injuries and effective for clinicians as a rehabilitative device. The company’s progress on its primary commercial priorities is illustrated in Exhibit 3 below.

Exhibit 3: Key objectives for 2015/16

Objectives

Progress

Initiation of clinical trials to demonstrate the clinical benefit and value of Rex to the rehabilitation community.

RAPPER II trial recruitment began in June 2015, with positive interim data already presented.

Implementation of a US clinical trial to win FDA 510(k) clearance of Rex for At-Home use in the US.

The company believes that a favourable review in a clinical trial could lead to clearance for At-Home use in late 2016.

Evidence of progress with other projects that demonstrate the value of Rex in accelerating the rehabilitation of patients who have experienced traumatic or degenerative neurological injury other than spinal cord injury.

The company is engaged in discussions with relevant hospitals. The Rex device is already starting to be used for rehabilitation therapy in indications other than SCI.

Recruitment of further reference centres to achieve target of 10 by year-end 2015.

The company expects to have eight reference centres operating by year-end 2015, with two more expected by the end of Q116.

Recruitment of distribution partners and other commercialisation initiatives.

Formed relationships with Enable Me in the US and MAAB in China.

Objectives

Initiation of clinical trials to demonstrate the clinical benefit and value of Rex to the rehabilitation community.

Implementation of a US clinical trial to win FDA 510(k) clearance of Rex for At-Home use in the US.

Evidence of progress with other projects that demonstrate the value of Rex in accelerating the rehabilitation of patients who have experienced traumatic or degenerative neurological injury other than spinal cord injury.

Recruitment of further reference centres to achieve target of 10 by year-end 2015.

Recruitment of distribution partners and other commercialisation initiatives.

Progress

RAPPER II trial recruitment began in June 2015, with positive interim data already presented.

The company believes that a favourable review in a clinical trial could lead to clearance for At-Home use in late 2016.

The company is engaged in discussions with relevant hospitals. The Rex device is already starting to be used for rehabilitation therapy in indications other than SCI.

The company expects to have eight reference centres operating by year-end 2015, with two more expected by the end of Q116.

Formed relationships with Enable Me in the US and MAAB in China.

Source: Rex Bionics, Edison Investment Research

Management change

As the company announced in September 2015, co-founder and chief technology officer Richard Little intends to resign from his position to develop a new business in a non-competitive field. He intends to continue working with Rex Bionics on a consultancy basis. We do not anticipate a significant impact on the company’s business, as Rex’s management team and board of directors have extensive experience in developing and bringing medical devices to market.

Valuation: Cheap on multiples, but execution is key

Following a 40% ytd drop in shares, Rex is trading at a significant discount to its peers on a price to sales basis, at only 1.5x FY17e sales vs an average of 11.9x CY16e (see Exhibit 4). Moreover, based on our current estimates, a reverse DCF with 15% WACC and 3% terminal growth implies that annual sales need to reach only c 130 units by 2020 to justify the share price. If the company’s sales follow an upward trend, clinical trials continue to show positive metrics and FDA clearance for the US personal market is obtained, we would expect these catalysts to help close the gap between Rex’s shares and those of its closest peers. That said, we note that execution remains key and any material delays in implementing the company’s growth strategy could affect our forecasts and valuation.

Exhibit 4 Rex Bionics peer group valuation

Year end 31 December

Market cap (US$m)

EV
(US$m)

Units in
use

P/Sales (x)

EV/Sales (x)

FY15e

FY16e

FY15e

FY16e

Ekso Bionics Holdings

134.7

123.5

92

15.1

9.8

13.8

9.0

ReWalk Robotics

181.0

156.0

97

47.5

14.0

40.9

12.0

Average

31.3

11.9

27.4

10.5

Source: Bloomberg. Note: Prices as at 5 January 2016.


Exhibit 5: Financial summary

£'000s

2012

2013

16m 2015

2016e

2017e

31-March

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

0

0

176

910

4,954

Cost of Sales

0

0

0

(662)

(1,978)

Gross Profit

0

0

176

248

2,976

EBITDA

 

 

(358)

(480)

(4,679)

(5,293)

(5,037)

Operating Profit (before amort. and except.)

(358)

(480)

(4,766)

(5,345)

(5,089)

Intangible Amortisation

0

0

(644)

(876)

(818)

Exceptionals

0

0

0

0

0

Other

0

0

0

6

0

Operating Profit

(358)

(480)

(5,410)

(6,215)

(5,907)

Net Interest

0

0

(63)

17

(378)

Profit Before Tax (norm)

 

 

(358)

(480)

(4,829)

(5,328)

(5,467)

Profit Before Tax (FRS 3)

 

 

(358)

(480)

(5,473)

(6,194)

(6,285)

Tax

0

0

172

0

0

Profit After Tax (norm)

(358)

(480)

(4,657)

(5,328)

(5,467)

Profit After Tax (FRS 3)

(358)

(480)

(5,301)

(6,194)

(6,285)

Average Number of Shares Outstanding (m)

25.9

33.9

9.9

16.1

17.8

EPS - normalised (p)

 

 

(1.4)

(1.4)

(46.9)

(33.2)

(30.7)

EPS - normalised and fully diluted (p)

 

(1.4)

(1.4)

(46.9)

(33.2)

(30.7)

EPS - (IFRS) (p)

 

 

(1.4)

(1.4)

(53.3)

(38.6)

(35.2)

Dividend per share (p)

0.0

0.0

0.0

0.0

0.0

Gross Margin (%)

N/A

N/A

100.0

27.3

60.1

EBITDA Margin (%)

N/A

N/A

N/A

N/A

N/A

Operating Margin (before GW and except.) (%)

N/A

N/A

N/A

N/A

N/A

BALANCE SHEET

Fixed Assets

 

 

0

0

14,022

13,343

12,773

Intangible Assets

0

0

13,771

12,895

12,077

Tangible Assets

0

0

251

448

696

Investments

0

0

0

0

0

Current Assets

 

 

386

184

5,082

2,826

8,141

Stocks

0

0

494

313

781

Debtors

4

10

220

146

781

Cash

382

174

4,368

2,367

6,579

Other

0

0

0

0

0

Current Liabilities

 

 

(112)

(390)

(595)

(1,964)

(2,994)

Creditors

(112)

(390)

(595)

(1,964)

(2,994)

Short term borrowings

0

0

0

0

0

Long Term Liabilities

 

 

0

0

(2,861)

(2,861)

(12,861)

Long term borrowings

0

0

0

0

(10,000)

Other long term liabilities

0

0

(2,861)

(2,861)

(2,861)

Net Assets

 

 

274

(206)

15,648

11,344

5,059

CASH FLOW

Operating Cash Flow

 

 

(109)

(208)

(4,814)

(3,668)

(5,110)

Net Interest

0

0

50

17

(378)

Tax

0

0

0

0

0

Capex

0

0

(391)

(250)

(300)

Acquisitions/disposals

102

0

0

0

0

Financing

389

0

9,349

1,900

0

Dividends

0

0

0

0

0

Net Cash Flow

382

(208)

4,194

(2,001)

(5,788)

Opening net debt/(cash)

 

 

0

(382)

(174)

(4,368)

(2,367)

HP finance leases initiated

0

0

0

0

0

Other

0

0

0

0

0

Closing net debt/(cash)

 

 

(382)

(174)

(4,368)

(2,367)

3,421

Source: Rex Bionics, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Rex Bionics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Share this with friends and colleagues